All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Syntonix Pharmaceuticals Inc. agreed to out-license overseas rights to FIX:Fc, its preclinical recombinant Factor IX product for hemophilia B, to Biovitrum AB. (BioWorld Today)